{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:01Z","timestamp":1787841301876,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T00:00:00Z","timestamp":1466208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.hemonc.2016.05.007","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T18:32:03Z","timestamp":1466706723000},"page":"168-169","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion"],"prefix":"10.4103","volume":"9","author":[{"given":"Mireille","family":"Crampe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Garry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Langabeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip T.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2016.05.007_b0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.822","article-title":"First and second line imatinib treatment in chronic myelogenous leukaemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts","volume":"25","author":"Andrikovics","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hemonc.2016.05.007_b0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cancergencyto.2007.04.013","article-title":"A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukaemia at accelerated phase and carrying the e19a2 BCR-ABL transcript","volume":"176","author":"Li","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.hemonc.2016.05.007_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2010.03.036","article-title":"A T315I mutation in e19a2 BCR\/ABL1 chronic myeloid leukaemia responding to dasatinib","volume":"34","author":"Cea","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.hemonc.2016.05.007_b0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cancergencyto.2010.05.012","article-title":"Chronic myeloid leukaemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib","volume":"201","author":"Martin","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.hemonc.2016.05.007_b0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7754\/Clin.Lab.2014.140818","article-title":"E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib","volume":"61","author":"Li","year":"2015","journal-title":"Clin Lab"},{"key":"10.1016\/j.hemonc.2016.05.007_b0030","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.leukres.2011.05.010","article-title":"Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukaemia","volume":"35","author":"Langabeer","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.hemonc.2016.05.007_b0035","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.2169\/internalmedicine.53.2578","article-title":"Molecular response to nilotinib in a patient with imatinib-intolerant e19a2-positive chronic myeloid leukaemia","volume":"53","author":"Kajiguchi","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.hemonc.2016.05.007_b0040","first-page":"871476","article-title":"Early complete molecular response to first-line nilotinib in two patients with chronic myeloid leukaemia carrying the p230 transcript","volume":"2013","author":"Greco","year":"2013","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.hemonc.2016.05.007_b0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fonc.2014.00017","article-title":"Nilotinib for the frontline treatment of chronic myeloid leukaemia carrying the p230 transcript: dream or reality?","volume":"4","author":"Capuozzo","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.hemonc.2016.05.007_b0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.51.1188","article-title":"Molecular response of e19a2 BCR-ABL1 chronic myeloid leukaemia with double Philadelphia chromosome to dasatinib","volume":"34","author":"Ikeda","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387616300322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387616300322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201609040-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:08Z","timestamp":1787838548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201609040-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2016.05.007","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}